Enliven Therapeutics (NASDAQ:ELVN) Insider Joseph Lyssikatos Sells 12,500 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) insider Joseph Lyssikatos sold 12,500 shares of Enliven Therapeutics stock in a transaction on Wednesday, November 19th. The shares were sold at an average price of $22.33, for a total transaction of $279,125.00. Following the transaction, the insider owned 902,688 shares in the company, valued at $20,157,023.04. The trade was a 1.37% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Enliven Therapeutics Price Performance

NASDAQ ELVN traded up $0.48 during trading hours on Friday, hitting $21.75. The company had a trading volume of 348,749 shares, compared to its average volume of 618,935. The firm’s 50 day moving average is $20.44 and its 200 day moving average is $20.15. Enliven Therapeutics, Inc. has a fifty-two week low of $13.30 and a fifty-two week high of $26.09. The company has a market capitalization of $1.29 billion, a price-to-earnings ratio of -11.82 and a beta of 0.80.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.11. On average, equities analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Hedge Funds Weigh In On Enliven Therapeutics

Several large investors have recently modified their holdings of ELVN. Vestal Point Capital LP increased its holdings in Enliven Therapeutics by 364.0% in the third quarter. Vestal Point Capital LP now owns 1,160,000 shares of the company’s stock valued at $23,745,000 after buying an additional 910,000 shares during the last quarter. TCG Crossover Management LLC bought a new stake in shares of Enliven Therapeutics in the 2nd quarter valued at approximately $9,990,000. Duquesne Family Office LLC raised its position in shares of Enliven Therapeutics by 104.6% during the 3rd quarter. Duquesne Family Office LLC now owns 947,405 shares of the company’s stock valued at $19,393,000 after acquiring an additional 484,405 shares in the last quarter. Candriam S.C.A. bought a new position in Enliven Therapeutics during the second quarter worth $8,358,000. Finally, Franklin Resources Inc. boosted its holdings in Enliven Therapeutics by 2,029.3% in the second quarter. Franklin Resources Inc. now owns 430,240 shares of the company’s stock worth $8,631,000 after purchasing an additional 410,034 shares during the period. Institutional investors own 95.08% of the company’s stock.

Analyst Upgrades and Downgrades

ELVN has been the subject of several recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen raised shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Enliven Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $41.20.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.